Abstract:The discovery of CRISPR/Cas has revolutionized the field of genome editing. CRIPSR/Cas components are part of the bacterial immune system and are able to induce double-strand DNA breaks in the genome, which are resolved by endogenous DNA repair mechanisms. The most relevant of these are the error-prone nonhomologous end joining and homology directed repair pathways. The former can lead to gene knockout by introduction of insertions and deletions at the cut site, while the latter can be used for gene correction based on a provided repair template. In this Account, we focus on the delivery aspects of CRISPR/Cas for therapeutic applications in vivo. Safe and effective delivery of the CRISPR/Cas components into the nucleus of affected cells is essential for therapeutic gene editing. These components can be delivered in several formats, such as pDNA, viral vectors, or ribonuclear complexes. In the ideal case, the delivery system should address the current limitations of CRISPR gene editing, which are (1) lack of targeting specific tissues or cells, (2) the inability to enter cells, (3) activation of the immune system, and (4) off-target events. To circumvent most of these problems, initial therapeutic applications of CRISPR/Cas were performed on cells ex vivo via classical methods (e.g., microinjection or electroporation) and novel methods (e.g., TRIAMF and iTOP). Ideal candidates for such methods are, for example, hematopoietic cells, but not all tissue types are suited for ex vivo manipulation. For direct in vivo application, however, delivery systems are needed that can target the CRISPR/Cas components to specific tissues or cells in the human body, without causing immune activation or causing high frequencies of off-target effects. Viral systems have been used as a first resort to transduce cells in vivo. These systems suffer from problems related to packaging constraints, immunogenicity, and longevity of Cas expression, which favors off-target events. Viral vectors are as such not the best choice for direct in vivo delivery of CRISPR/Cas. Synthetic vectors can deliver nucleic acids as well, without the innate disadvantages of viral vectors. They can be classed into lipid, polymeric, and inorganic particles, all of which have been reported in the literature. The advantage of synthetic systems is that they can deliver the CRISPR/Cas system also as a preformed ribonucleoprotein complex. The transient nature of this approach favors low frequencies of off-target events and minimizes the window of immune activation. Moreover, from a pharmaceutical perspective, synthetic delivery systems are much easier to scale up for clinical use compared to viral vectors and can be chemically functionalized with ligands to obtain target cell specificity. The first preclinical results with lipid nanoparticles delivering CRISPR/Cas either as mRNA or ribonucleoproteins are very promising. The goal is translating these CRISPR/Cas therapeutics to a clinical setting as well. Taken together, these current trends seem to favor the use of sgRNA/Cas ribonucleoprotein complexes delivered in vivo by synthetic particles.

Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy

Nanotechnology‐based CRISPR/Cas9 delivery system for genome editing in cancer treatment

Progress of delivery methods for CRISPR-Cas9

Advances in delivery systems for CRISPR/Cas-mediated cancer treatment: a focus on viral vectors and extracellular vesicles

In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges

Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment

CRISPR/Cas9-based application for cancer therapy: Challenges and solutions for non-viral delivery

Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for in Vivo CRISPR/Cas-Based Genome Editing.

Rational designs of in vivo CRISPR-Cas delivery systems

Delivery of CRISPR/Cas9 for Therapeutic Genome Editing

Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing

Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications

Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing

Development of CRISPR/Cas Delivery Systems for In Vivo Precision Genome Editing

Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy

Delivering the CRISPR/Cas9 system for engineering gene therapies: Recent cargo and delivery approaches for clinical translation

Delivering CRISPR: a review of the challenges and approaches

Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets

Strategies for organic nanoparticles delivering CRISPR/Cas9 for cancer therapy: Challenges and breakthroughs

Approach for in vivo delivery of CRISPR/Cas system: a recent update and future prospect

Nano-vectors for CRISPR/Cas9-mediated genome editing